C. Fournelfleury et al., GROWTH FRACTIONS IN CANINE NON-HODGKINS-LYMPHOMAS AS DETERMINED IN-SITU BY THE EXPRESSION OF THE KI-67 ANTIGEN, Journal of Comparative Pathology, 117(1), 1997, pp. 61-72
The proportion of proliferating cells in non-Hodgkin's lymphomas (NHLs
) as determined in situ by the expression of the Ki-67 antigen, has pr
ognostic value in human oncology, and is strongly related to the diffe
rent grades of malignancy. The evaluation of the Ki-67 index in canine
NHLs may be useful in assessing the individual variability of the gro
wth fraction in the different sub-types of lymphoma, and also the vali
dity or the classification in terms of grade of malignancy. The growth
fraction was evaluated in 92 canine NHLs, previously classified accor
ding to the Kiel classification (as adapted to the canine species), by
determining the expression of the Ki-67 antigen with the MIB1 antibod
y on (1) paraffin-wax tissue sections in all 92 cases, and (2) fine-ne
edle aspirates or tumour imprints in 30 cases. The labelling appeared
satisfactory in 88% of the cases, with good concordance between the hi
stological and cytological data. A highly significant correlation (P<0
.001) was established between the proportion of Ki-67(+) cells and the
classification into low-grade (Ki-67 index <21%) and high-grade malig
nancy (Ki-67 index >21% and usually >29%). In the low-grade lymphoma g
roup, a macronucleolated medium-sized-cell lymphoma not found in man b
ad the lowest proliferation index. In the high-grade malignancy group,
the number of Ki-67(+) cells seemed to be proportional to cell size,
whatever the phenotype, with the rare exceptions of some unclassifiabl
e small cell Burkitt-type or plasmacytoid lymphomas, which were highly
proliferating. The classification of lymphomas into low-grade and hig
h-grade appears to correlate well with their proliferative index. The
existence of individual variations, within given categories of canine
NHL, suggests that, as in human medicine, prognosis may be assisted by
determining the growth fraction at initial diagnosis, and by fine-nee
dle aspiration at relapses. (C) 1997 W.B. Saunders Company Limited.